Safety and Efficacy of Phenylpropanolamine and Phenylephrine

Critical Safety Distinction

The American College of Cardiology and American Heart Association recommend completely avoiding phenylpropanolamine in all hypertensive patients due to significant blood pressure effects 1

Meta-analysis of 33 trials with 2,165 patients demonstrated that phenylpropanolamine increased systolic blood pressure by 5.5 mmHg and diastolic blood pressure by 4.1 mmHg 2, 3, 4
Phenylpropanolamine causes substantially greater blood pressure elevation than pseudoephedrine, which only increases systolic blood pressure by 0.99 mmHg 4, 1

Phenylephrine's efficacy as an oral decongestant has not been well established, and it is extensively metabolized in the gut, making it less effective than other decongestants 5, 6

Given that phenylpropanolamine poses significant cardiovascular risks while phenylephrine is ineffective but safe, neither agent represents an optimal choice for nasal congestion 5, 1

Intranasal corticosteroids are the most effective and safest option for nasal congestion, with no cardiovascular risk 5, 1
Pseudoephedrine remains more effective than phenylephrine, with only minimal blood pressure effects in most patients 4, 1
Topical decongestants, such as oxymetazoline, for short-term use provide superior efficacy to oral agents with minimal systemic absorption 6, 1

Both agents should be used with extreme caution or avoided entirely in patients with cardiac arrhythmia, angina pectoris, cerebrovascular disease, hypertension, hyperthyroidism, bladder neck obstruction, or glaucoma 2, 3, 6, 1

Do not assume phenylephrine is an adequate substitute for pseudoephedrine when regulatory restrictions apply - it lacks proven efficacy despite being non-restricted 5, 3
Never combine phenylpropanolamine with caffeine or other stimulants - additive adverse effects including elevated blood pressure, insomnia, and palpitations occur 2, 3
Do not use either agent in children under 6 years - oral decongestants have been associated with agitated psychosis, ataxia, hallucinations, and death in young children 2, 5